NASDAQ : SNTI
Senti Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.217 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 6.76M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 5.14M |
| Enterprise Value | 18.76M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 31.14M |
| Shares Outstanding | 31.14M |
| Shares Change (YoY) | +155.08% |
| Shares Change (QoQ) | +0.56% |
| Owned by Insiders (%) | 2.15% |
| Owned by Institutions (%) | 6.99% |
| Float | 12.00M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 93.49 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 341.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.83 |
| Quick Ratio | 0.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -466.46% |
| Return on Assets (ROA) | -65.57% |
| Return on Invested Capital (ROIC) | -91.57% |
| Return on Capital Employed (ROCE) | -307.49% |
| Weighted Average Cost of Capital (WACC) | 3.33% |
| Revenue Per Employee | $1,410 |
| Profits Per Employee | -$1.27M |
| Employee Count | 39 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 2.22 |
| 52-Week Price Change | -92.32% |
| 50-Day Moving Average | 0.30 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 29.90 |
| Average Volume (20 Days) | 9,879,596 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 427,404 |
| Short Previous Month | 487,169 |
| Short % of Shares Out | 1.37% |
| Short % of Float | 3.56% |
| Short Ratio (days to cover) | 0.23 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 55,000 |
| Gross Profit | -31.27M |
| Operating Income | -53.32M |
| Pretax Income | -49.56M |
| Net Income | -49.56M |
| EBITDA | -50.17M |
| EBIT | -53.32M |
| Loss Per Share | -$1.71 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 6.61M |
| Total Debt | 20.23M |
| Net Cash | -13.62M |
| Net Cash Per Share | -$0.44 |
| Equity (Book Value) | -3.40M |
| Book Value Per Share | -0.11 |
| Working Capital | -2.76M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -38.05M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 3.15M |
| Net Borrowing | 9.70M |
| Free Cash Flow | -38.05M |
| FCF Per Share | -$1.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -96,943.64% |
| Pretax Margin | -90,116.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -155.08% |
| Shareholder Yield | -155.08% |
| Earnings Yield | -1,036.37% |
| FCF Yield | -740.00% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $13.50 |
| Price Target Difference | 8,076.86% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 676.49% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jul 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -20.69 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |